Adalvo announces successful DCP Submission for Dapagliflozin

We are pleased to announce our successful DCP submission for Dapagliflozin 10mg film-coated tablets. This product has been developed in collaboration with one of our strategic partners.

Our product has been developed based on the reference brand Forxiga 10mg film-coated tablets, which is indicated in children, aged 10 years and above, for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, and in adults for the treatment of symptomatic chronic heart failure and chronic kidney disease.

The brand sold approximately $8bn globally in 2022, having a significant growth potential with Global 3Y CAGR at +35%, according to IQVIA. 

Partner up now! 

At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.

[email protected] – Central & Eastern Europe, Russia & CIS
[email protected] North Europe, APAC, MENA & Israel
[email protected] – Brazil
[email protected] - LATAM (exc. Brazil) & South Europe
[email protected] – Europe
[email protected] – UK/Ireland, North America & South Africa
[email protected] - LATAM (exc. Brazil)

[email protected] - Head of Global BD&L

Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.